Skip to main content
. Author manuscript; available in PMC: 2016 Jan 5.
Published in final edited form as: J Am Coll Cardiol. 2013 Nov 12;63(25 0 0):2935–2959. doi: 10.1016/j.jacc.2013.11.005

Table 6.

Expert Opinion Thresholds for use of Optional Screening Tests When Risk-Based Decisions Regarding Initiation of Pharmacological Therapy are Uncertain Following Quantitative Risk Assessment

Measure Support Revising Risk Assessment
Upward		 Do Not Support Revising Risk
Assessment
Family history of
premature CVD		 Male <55 years of age
Female <65 years of age
(1st degree relative)		 Occurrences at older ages only (if any)
hs-CRP ≥2 mg/L <2 mg/L
CAC score ≥300 Agatston units or ≥75th percentile for
age, sex, and ethnicity* 		<300 Agatston units and <75 percentile for
age, sex, and ethnicity*
ABI <0.9 ≥0.9
*

For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.

ABI indicates ankle-brachial index; CAC, coronary artery calcium; CVD, cardiovascular disease; and hs-CRP, high-sensitivity C-reactive protein.